Clinical trials: Schwannoma, Vestibular
Schwannoma, Vestibular, Neurofibromatosis 2
NF2 Natural History Consortium
OBJECTIVES: I. Define the growth rates and clinical course of NF2-related tumors in patients with neurofibromatosis type 2. Associate growth rate with physical function.
- Conditions
- Schwannoma, Vestibular, Neurofibromatosis 2, Meningioma
- Trial name
- NCT00004483
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- House Ear Institute
Acute Unilateral Vestibular Deafferentiation
Unravelling Risk Factors for Chronic Dizziness in Patients After an Acute Unilateral Vestibular Deafferentiation.
In many patients with an acute unilateral vestibular deafferentiation (uVD) syndrome symptoms are expected to resolve spontaneously because of central compensation.
- Trial name
- Activation (NCT04979598)
- Testing
- Home exercise program
- Where
- Belgium
- Volunteers
- 103 people
- Sponsor
- Universiteit Antwerpen
Vestibular Schwannoma
Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma
Surgical removal of vestibular schwannoma causes acute vestibular symptoms, including postoperative vertigo and oscilopsia due to nystagmus. In general, the dominant symptom postoperatively is vertigo.
- Trial name
- ITG (NCT02963896)
- Testing
- gentamicin
- Volunteers
- 20 people
- Sponsor
- University Hospital, Motol
Vestibular Schwannoma
Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
Vestibular schwannomas (VS) arise from the vestibulocochlear (hearing and balance) nerve, located at the base of the brain. Although benign, VS can enlarge over time, resulting in debilitating symptoms; therefore, surgical…
- Trial name
- NCT04057976
- Testing
- Probabilistic diffusion tensor tractography
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- King's College Hospital NHS Trust
Vestibular Schwannoma, Acoustic Neuroma
Study of Aspirin in Patients With Vestibular Schwannoma
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
- Conditions
- Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
- Trial name
- NCT03079999
- Testing
- Aspirin
- Where
- 5 sites in United States
- Volunteers
- 97 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Vestibular Schwannoma
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product…
- Trial name
- NCT06517888
- Testing
- AAVAnc80-antiVEGF via Akouos Delivery Device
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Akouos, Inc.
Neurofibromatosis 2, Vestibular Schwannoma
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
The purpose of this study is to determine if Lapatinib has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2). NF2 is a condition that mainly affects the skin and nervous system.
- Trial name
- NCT00973739
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
This phase I trial studies the side effects and best dose of gamma-secretase/Notch signalling pathway inhibitor RO4929097 (RO4929097) when given together with temozolomide and radiation therapy in treating patients with newly…
- Conditions
- Acoustic Schwannoma, Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
- Trial name
- NCT01119599
- Testing
- 3-Dimensional Conformal Radiation Therapy, Gamma-Secretase Inhibitor RO4929097, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Vestibular Schwannoma, Visual Impairment
Consequence of Unilateral Vestibular Loss on Visual Abilities
Unilateral vestibular lesions are frequent and disabling pathologies causing a set of oculomotor, postural and perceptual symptoms. These symptoms reduce over time according to a vestibular compensation.
- Conditions
- Vestibular Schwannoma, Visual Impairment, Vestibular Meniere Syndrome
- Trial name
- SVorthoptie (NCT03581331)
- Testing
- orthoptic balance
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Vestibular Schwannoma
Remote Ischemic Preconditioning in Vestibular Schwannoma Surgery
Vestibular schwannomas are primarily benign (WHO grade I) tumors originating from the Schwann cells of the vestibular nerve and are among the most common tumors of the skull base.
- Trial name
- RIC-VS (NCT05567341)
- Testing
- Remote ischemic preconditioning
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital Tuebingen
Acute Peripheral Vestibulopathy Following Surgical Procedure
The Use of Virtual Reality in Rehabilitation in Patients After Vestibular Schwannoma Surgery.
Resection of the vestibular schwannoma leads to acute peripheral or combined vestibular loss caused by a surgical lesion to the branches of the vestibular nerve and, less frequently also the lesion of the cerebellum.
- Trial name
- NCT05578560
- Testing
- Prehabituation, 3D optokinetic stimulation in virtual reality space, Vestibular training
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Charles University, Czech Republic
Vestibular Schwannoma, Hearing Loss
Intraoperative EABR for Decision Making
In this study patients undergoing simultaneous translabyrinthine vestibular schwannoma resection and cochlear implantation are included. The goal of the study is to correlate the eABR results with postoperative hearing results.
- Trial name
- NCT03745560
- Where
- Austria
- Volunteers
- 15 people
- Sponsor
- Christoph Arnoldner
Vestibular Schwannoma, Vestibular Schwannomas
Vestibular Rehabilitation Protocol in Unilateral Vestibular Schwannoma
Brief Summary The purpose of this clinical trial is to evaluate whether different strategies of vestibular rehabilitation, performed before and after surgery, can improve recovery in adults diagnosed with unilateral vestibular…
- Trial name
- NCT07364955
- Testing
- No Intervention: Observational Cohort, Structured home-based vestibular telerehabilitation program, CE-marked clinical rotatory chair
- Where
- Spain
- Volunteers
- 75 people
- Sponsor
- Albert Torrents Torrero
Neurofibromatosis Type 2, Neuroma, Acoustic
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
The purpose of the study is to determine if RAD001 treatment will shrink or slow the growth of the vestibular schwannoma(s) in Neurofibromatosis 2 (NF2) patients.
- Trial name
- NCT01345136
- Testing
- RAD001, everolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Neuroma, Acoustic
Impact of Shared Decision-Making With Decision Aids on Acoustic Neuroma Treatment Choice: A Randomized Controlled Trial
Patients with acoustic neuroma had several treatment options. One of standard treatment is to receive the Gamma knife stereotactic radiosurgery, other options included suboccipital craniotomy and conservative treatment.
- Trial name
- NCT04101409
- Testing
- Decision aids
- Volunteers
- 78 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Vestibular Schwannoma
Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF
Patients undergoing surgery of a vestibular schwannoma will be included in the study. Patients will receive triamcinolone acetonide 24h before surgery.
- Trial name
- NCT04658836
- Testing
- Triamcinolone Acetonide 40mg/mL
- Where
- Austria
- Volunteers
- 21 people
- Sponsor
- Medical University of Vienna
Neurofibromatosis 2
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
OBJECTIVES: I. Define the tonotopocity of multichannel brain stem stimulation and use this information to better program the auditory brain stem implant for an individual. II.
- Trial name
- NCT00004437
- Testing
- Multichannel Auditory Brain Stem Implant
- Sponsor
- FDA Office of Orphan Products Development
Vestibular Schwannoma, Glioma, Astrocytic
USPIO Enhanced MR Imaging in CNS Tumours (UMIC)
The immune response or inflammation is known to be a key driver of progression and growth in many solid tumours. Inflammatory cells called macrophages are present in high numbers in many brain tumours and these tumour associated…
- Trial name
- UMIC (NCT06572475)
- Testing
- USPIO enhanced MRI
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Northern Care Alliance NHS Foundation Trust
Neurofibromatosis 2
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Bevacizumab can be an effective treatment for individuals with NF2 and improve different nerve functions (like hearing, tinnitus or balance problems) and the quality of life of NF2 patients.
- Trial name
- NCT05685836
- Testing
- Bevacizumab Zirconium Zr-89
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Leiden University Medical Center
Meningioma, Glioblastoma
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer
- Trial name
- NCT07493447
- Testing
- Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eben Rosenthal